Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

Part of paid clinical trials in Houston, Texas.

Sponsor
Mohammad H. Abu Arja
Study ID
NCT07242963
Status
Recruiting
Apply to this trial

Conditions

  • Medulloblastoma Recurrent
  • Medulloblastoma, Childhood, Recurrent
  • Medulloblastoma, SHH-activated and TP53 Mutant
  • Medulloblastoma, SHH-activated and TP53 Wildtype

Eligibility Criteria

Sex
ALL
Age
3 Years - 50 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Cancer Center. A biobank is a facility that stores and manages biological samples (such as blood, tissue, or DNA) from individuals, along with detailed health information, for use in medical research to study diseases and develop new treatments. The investigators are requesting participants' permission to add their information and samples to this biobank. Being in this research study is voluntary; it is the participant's choice. If the participant joins this study, they can still stop at any time. If the participant decides to participate, the investigators will review the participant's clinical medical records, demographics, treatment history, family history, and imaging. The investigators will also collect biological samples from the participant and the biological parents' buccal swabs (optional). The participation in this biobank will last about 5 years from the decision to participate. Why am I being asked to participate? The participant or their child is invited to participate in this study if the participant or their tumor may have a U1 mutation. U1 mutation is associated with an error in the gene that splices the tumor DNA, leading to random splicing that may increase the tumor mutation burden and generate novel tumor neoantigens (targets). Studying the U1 mutation will enable the investigator to design more effective therapies and guide future treatments for patients with relapsed or refractory sonic hedgehog medulloblastoma, thereby improving their outcomes and quality of life. Moreover, the investigators aim to determine whether germline mutations inherited from parents may increase the risk of medulloblastoma in their offspring. The participant will receive no direct benefit from their participation in this study. However, participation in this study may help the investigators better understand SHH Medulloblastomas and benefit other patients in the future.

Key Dates

Start date
Sep 30, 2025
Status verified
Apr 2026
Primary completion
Dec 30, 2035
Completion
Dec 30, 2035

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Group 1
    Patients treated at registry institutions
  • Arm: Group 2
    Patients not treated at registry institutions
  • Arm: Group 3
    Biological parents of a subject participating in Group 1 or 2

Primary Outcome Measure

To describe the incidence of the U1 mutation in SHH medulloblastoma subtypes and verify the feasibility of U1 testing. The primary outcome will be detecting the U1 mutation by polymerase chain reaction (PCR) testing or RNA sequencing (RNAseq). [ Time Frame: Through study completion, an average of 2 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Baylor College of MedicineHoustonTexas77004
Mohammad H Abu-Arja, MD, MSc
[email protected]
832-824-0592
Ta-Tara Rideau
[email protected]
MD Anderson Cancer CenterHoustonTexas77030
Gregory K Friedman, MD
[email protected]
713-792-6620 , 713-792-2121
Lauren E Fuller
[email protected]
832-829-0613

Find similar trials in Houston, TX

By research site
Baylor College of Medicine· Houston, TXMD Anderson Cancer Center· Houston, TX

Related Studies